New heart failure device impresses | Cardiac amyloidosis in the spotlight | Experts agree: HFmrEF should not be ignored

This new catheter-based device for lymphatic drainage showed early potential to be an effective treatment option for acute decompensated heart failure.

Cardiac amyloidosis continues to get more and more attention at cardiology meetings. At Heart Failure 2026 in Spain, it was the topic of multiple studies, including one on the benefits of acoramidis.

Data from BENEFIT-HF, a new randomized study of CVRx's implantable Barostim device, could open up access to many more heart failure patients. 

Data on the treatment and management of HFmrEF are limited, but a new scientific statement from the Heart Failure Society of America highlights how important it is to take this condition seriously.

This is the second FDA clearance in two weeks for Massachusetts-based Anumana. The company's AI models are built to evaluate ECG results for signs of various cardiovascular conditions.

A majority of deaths from Friedreich's ataxia are associated with heart complications. A new treatment years in the making could provide some much-needed relief.

Pulnovo Medical, a global medtech company, plans on using the funds for clinical development, regulatory submissions, commercialization and much more. 

Researchers noted that these requirements are more common for Black and Hispanic patients, creating a critical barrier to guideline-recommended care.